ARCHIVES

Phase III Trebananib Trial Fails OS Endpoint In Recurrent Platinum-Resistant Ovarian Cancer

This article is from The Cancer Letter archive.

Vol. 37 No. 11 | November 28, 2014

Download PDF Visit The Full Archive

Related Articles

Cancer Letter Goes On Vacation

August 16, 1985

Amgen Cancels Rilotumumab Trials in Gastric Cancer

December 26, 2014

NCI Cooperative Group, Cancer Center Trials Listed

June 29, 2007

DoD Ovarian Cancer Research Program seeks proposals for FY05 funding.

October 1, 2004

NCI to Advise Women in 40s o Ask Doctor About Mammography, End Routine Screening

September 24, 1993

NTP Panel Agrees PBB Carcinogenic, Two Asbestos Varieties Are Not

July 3, 1981